Ascendis Pharma Growth Disorders A/S

5 trials 3 recruiting Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

3 Recruiting

2 Completed trials

11 Countries active

3 Unique IMPs

100% Results reported

Phase II

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

NAVEPEGRITIDE 4 C-TYPE NATRIURETIC PEPTIDE CONJUGATED TO A MULTI-ARM POLYETHYLENE GLYCOL CARRIER MOLECULE THROUGH A CLEAVABLE LINKER 1 LONAPEGSOMATROPIN 1

All trials

5 total

A Phase 2 Clinical Trial to Investigate Safety, Tolerability and Efficacy of TransCon CNP, Weekly Subcutaneous Injections, Compared with Pla… Recruiting

2023-506091-27-00 Phase II 11 countries NAVEPEGRITIDE
Efficacy and Safety of Navepegritide in Adolescents with Achondroplasia Recruiting

2024-514208-15-00 Phase II 3 countries NAVEPEGRITIDE
AttaCH: A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of… Recruiting

2022-502202-33-00 Phase II 10 countries NAVEPEGRITIDE
COACH: A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepe… Ended

2023-508341-40-00 Phase II 2 countries LONAPEGSOMATROPIN; NAVEPEGRITIDE
A phase 2b clinical trial to evaluate efficacy and safety of weekly doses of TransCon CNP compared with placebo in participants with achondr… Ended

2024-515469-32-00 Phase II 3 countries C-TYPE NATRIURETIC PEPTIDE CONJUGATED TO A MULTI-ARM POLYETHYLENE GLYCOL CARRIER…

Showing 1–5 of 5 trials

← All sponsors A–Z